Moderna’s mission is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Moderna's COVID-19 Vaccine

Our platform continues to play an important role in supporting a rapid response to the global pandemic, and our COVID-19 Vaccine is now authorized for use in more than 35 countries.

Phase 3 COVE study

37% of enrolled participants were from communities of color, similar to the diversity of the U.S. population

Commitment to vaccines and therapeutics access

Aiming to provide effective and affordable vaccines and therapeutics to all populations

Intellectual property

Not enforcing our COVID-19 related patents against those making vaccines while the pandemic continues

Investments in global manufacturing

Working to manufacture up to one billion doses by the end of 2021

Development pipeline

Our focus is to use our platform and the infrastructure we’ve built to address infectious and serious diseases.

24 development programs

Public health portfolio: Zika, HIV, and Nipah vaccines

Rare disease programs including Propionic Acidemia (PA), Methylmalonic Acidemia (MMA) & more

$1.37 billion R&D investment in 2020